SUPPLEMENT

Q1 2023 — Quarterly update

Q1 2023PDF · 3 pages152 KB
MSCI Inc. Quarterly Update
April 25, 2023
MSCI remains well-positioned to deliver mission-critical tools, solutions and content investors need to
build more effective portfolios.
Addressing the Needs of Clients and Client Segments
• 	Launch of MSCI Corporate Sustainability Insights: Corporate issuers increasingly need tools to
understand the ESG and climate challenges and opportunities facing their companies. During the
quarter, we launched MSCI Corporate Sustainability Insights – a solution that gives executives at
listed companies tracked by MSCI ESG Research the ability to measure and compare their ESG and
climate data versus peers, while also identifying potential disclosure gaps, through intuitive charts,
graphs and maps. MSCI Corporate Sustainability Insights is also designed to provide corporate
issuers with views into their climate risk exposure and alignment with global temperature goals
with access to relevant information from MSCI ESG Research’s Climate Value-at-Risk and Implied
Temperature Rise solutions.
• 	Published Climate Market Overview Report on Real Capital Analytics (RCA) platform: To support
commercial real estate investor clients as they continue to factor in the impact of climate change,
we have released a new report on the RCA platform to generate climate insights related to
Commercial Real Estate markets. The report measures the distribution of climate risk across
markets and property types. The report complements the detailed asset-level factsheet that we
delivered in 2022 and gives users the big-picture view across a single or multiple markets and
provides details across physical and transition risks.
• 	Launch of MSCI Float Data Product: To address demand from broker dealer and hedge fund
clients, during the quarter we launched the MSCI Float Data Product, a new offering created to
provide additional transparency related to free float market capitalization at a security level. Free
float market capitalization is one of the inputs in the construction of MSCI indexes. This extensive
data set includes all securities within the MSCI equity universe and is updated on a monthly basis.
• 	During the quarter we won several awards and received several recognitions:
o 	MSCI ESG Research’s Implied Temperature Rise won “Most Innovative ESG Product” of the
year at ESG Investing Awards 2023. MSCI Implied Temperature Rise equips investors with a
metric that plots how companies or portfolios align with global temperature targets.
o 	MSCI won the “Best Smart Beta Index Provider” award at the SRP Europe Awards 2023. SRP
is the leading provider of intelligence for the global structured product market and recognizes
industry leading talent through their awards programs.
o 	MSCI accepted four “best index provider” ETF Express European Awards for 2023, recognizing
our success in the growing ETF industry and our commitment to meeting a range of diverse
benchmark needs for investors. We won in the following categories: Best European Index
Overall Provider, Best Index Provider – Equity ETFs, Best Index Provider – ESG ETFs and
Best Index Provider – Emerging Markets ETFs.

-- 1 of 3 --

2
1Q23 QUARTERLY UPDATE
Launching Innovative Solutions and Products
• 	Launch of New Japan Equity Factor Models: We launched the next generation of MSCI Japan
Equity Factor Models. Designed to help investors better understand the factors that drive portfolio
risk and performance as market conditions change, the model features three new factors,
Sustainability, Crowding and Machine Learning. Building on MSCI’s five decades of factor research,
and developed in consultation with some of the world’s largest investors, the latest models enable
institutional investors to construct portfolios across new and familiar factor dimensions; run
comparisons to industry peers and benchmarks; and provide enhanced transparency into portfolio
characteristics through improved handling of IPOs, improved coverage, and dynamic industry
exposure analysis.
• 	Launch of the MSCI ACWI IMI Immuno-oncology Index, developed in collaboration with Royalty
Pharma: We launched the MSCI ACWI IMI Immuno-oncology Index, the second Index in our new
Life Sciences suite of indexes developed in collaboration with Royalty Pharma. This new index
follows the launch of ACWI IMI Virology Index last year. The MSCI ACWI IMI Immuno-oncology
Index aims to represent the performance of a set of companies that are associated with research,
development, and commercialization of products for cancer immunotherapy, also known as
Immuno-oncology. Immuno-oncology is a form of cancer treatment that uses the power of the
body’s own immune system to prevent, control and eliminate cancer. The new index can be utilized
for investment universe identification, internal research, benchmarking and as the basis for ETFs,
structured products or other index-linked investments.
• 	Launch of Integrated Market and Credit Model: The Integrated Market and Credit Model (IMC) is a
newly launched comprehensive model that quantifies the impact of market movements and
default events across short and long investment horizons, to allow clients to measure and manage
both sources of risk together. IMC offers a single, consistent framework in place of disjointed
solutions that are costly to operate and are less effective. By integrating important aspects of both
market and default events into IMC, clients are now able to better express views about
probabilities of default, recovery rates, credit drivers and reinvestment rates to tailor analyses to
their investment horizons and to generate various scenarios to test on their portfolios. Clients can
access this innovative model seamlessly through MSCI RiskManager.
Enhancing Capabilities with Data, Technology and through Partnerships
• 	Strategic Collaboration with Salt Financial to create risk-controlled index solutions for insurance
companies: During the quarter, MSCI announced a strategic collaboration with Salt Financial to
provide insurance companies and their clients with a new way to leverage MSCI’s 50 years of
expertise in research and index construction using Salt’s patent-pending truVol® Risk Control
Engine (RCE). The use of historical intraday data for volatility forecasting in truVol is designed to
help increase volatility targeting accuracy and responsiveness for risk-controlled indexes.
Combining MSCI's expertise in index construction and Salt’s truVol technology, we intend to create
highly differentiated risk-controlled indexes for use in the indexed annuity market. Retirement
solutions are in great demand, fueled by an aging population, volatile and uncertain markets, and
investors’ desire for principal-protected products.

-- 2 of 3 --

3
1Q23 QUARTERLY UPDATE
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over
50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to
understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-
leading research-enhanced solutions that clients use to gain insight into and improve transparency across the
investment process. To learn more, please visit www.msci.com.
About MSCI ESG Research Products and Services
MSCI ESG Research products and services are provided by MSCI ESG Research LLC, and are designed to provide in-
depth research, ratings and analysis of environmental, social and governance-related business practices to companies
worldwide. ESG ratings, data and analysis from MSCI ESG Research LLC are also used in the construction of the MSCI
ESG Indexes which are not subject to our SEC registration. MSCI indexes are products of MSCI Inc., and MSCI Limited is
the benchmark administrator. MSCI ESG Research LLC is a Registered Investment Adviser under the Investment
Advisers Act of 1940 and a subsidiary of MSCI Inc. MSCI ESG Research materials, including materials utilized in any
MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States
Securities and Exchange Commission or any other regulatory body.
FORWARD-LOOKING STATEMENTS
This quarterly update contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause MSCI’s actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance or
achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by
the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,”
“potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue
reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity,
performance or achievements.
Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in
MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange
Commission (“SEC”) on February 10, 2023 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or
furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be
incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this quarterly
update reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties
and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no
obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new
information, future events, or otherwise, except as required by law.

-- 3 of 3 --